Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Steinmann

Showing results (51-60 of 57) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 57 results.
Hepatology (Baltimore, Md.)|February 26, 2005
Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis CMarkus Reiser, Holger Hinrichsen, Yves Benhamou, et al.
Melanoma Research|December 22, 1999
Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II studyD Liénard, A M Eggermont, H S Koops, et al.
Antiviral Therapy|June 9, 2006
Viral kinetics in patients with chronic hepatitis C treated with the serine protease inhibitor BILN 2061Eva Herrmann, Stefan Zeuzem, Christoph Sarrazin, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 11, 2014
Mechanisms underlying benign and reversible unconjugated hyperbilirubinemia observed with faldaprevir administration in hepatitis C virus patientsRucha S Sane, Gerhard G Steinmann, Qihong Huang, et al.
Gastroenterology|November 3, 2004
Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patientsHolger Hinrichsen, Yves Benhamou, Heiner Wedemeyer, et al.
Hepatology (Baltimore, Md.)|January 30, 2013
Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trialMark S Sulkowski, Tarik Asselah, Jacob Lalezari, et al.
Hepatology (Baltimore, Md.)|March 19, 2013
Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trialMark S Sulkowski, Marc Bourlière, Jean-Pierre Bronowicki, et al.
Pageof 6

Showing results (51-60 of 57) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
Hepatology (Baltimore, Md.)|February 26, 2005
Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis CMarkus Reiser, Holger Hinrichsen, Yves Benhamou, et al.
Melanoma Research|December 22, 1999
Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II studyD Liénard, A M Eggermont, H S Koops, et al.
Antiviral Therapy|June 9, 2006
Viral kinetics in patients with chronic hepatitis C treated with the serine protease inhibitor BILN 2061Eva Herrmann, Stefan Zeuzem, Christoph Sarrazin, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 11, 2014
Mechanisms underlying benign and reversible unconjugated hyperbilirubinemia observed with faldaprevir administration in hepatitis C virus patientsRucha S Sane, Gerhard G Steinmann, Qihong Huang, et al.
Gastroenterology|November 3, 2004
Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patientsHolger Hinrichsen, Yves Benhamou, Heiner Wedemeyer, et al.
Hepatology (Baltimore, Md.)|January 30, 2013
Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trialMark S Sulkowski, Tarik Asselah, Jacob Lalezari, et al.
Hepatology (Baltimore, Md.)|March 19, 2013
Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trialMark S Sulkowski, Marc Bourlière, Jean-Pierre Bronowicki, et al.
Pageof 6